Danielle Barron talks to author Ron Adner whose book “The Wide Lens” explains why the failure to focus on the entire ecosystem rather than the immediate environment of a new product is the downfall of pharmaceutical companies attempting to successfully commercialize innovation.
With a staggering cost of drug development estimated at US$2.6 billion and a high failure rate of new compounds, pharma is under pressure to develop solutions that improve the R&D hit rate. Real World Evidence combined with digital healthcare might be what the industry is looking for.
“For the natural born innovator, risk and failure are akin to an old, comfortable pair of shoes” - Henry Doss, ecosystem architect and co-author of ‘The Rainforest Scorecard: A Practical Framework for Growing Innovation Potential.’ We investigate how a culture of innovation can be created.
We speak to co-author of The Innovator’s Method, Nathan Furr, about how pharma can enhance innovation, decrease costs, and accelerate drug discovery time frames with fast and frugal experiments in the face of uncertainty.
The merging of the modern advent of the public Twittersphere with the traditional methodology of clinical trials has provided a patient-centric, patient-driven, and patient-funded opportunity within disease treatment research.
Oral cancer drugs can offer a more convenient alternative to traditional IV therapies when it comes to treating patients, but issues such as adherence and reimbursement still need to be ironed out, while payers have to be convinced that oral agents represent value for money.
Positive patient experiences and patient outcomes with high recruitment, adherence and retention result from alignment of the HEART, HEAD and HANDS within the research sponsor’s organization and among all key stakeholders.
There is consensus around the idea that greater access to patient-level clinical data is a good thing – good for science, business and humanity. However, sharing data brings with it a host of benefits, questions and risks for the industry.